Philippe Le Goff

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development

Bioring SA is a venture-backed company which designs, develops and markets new biodegradable medical devices and implants improving treatment outcome and reducing post treatment risk and complications. The Company's products originate from a proprietary know-how in chemical engineering and manufacturing which results in a unique technology platform combined with an expertise in medical device design and development. The Company's products find applications across the board, with a primary focus on cardiac surgery and urology. They can be implanted in standard open surgery as well as minimally invasive surgery, with or without a catheter. Bioring is funded by CDC Innovation, a leading French venture capital group, in addition to a number of business angels. The Company has taken its first product to the market in cardiac surgery in 2005 and has ongoing developments of other cardiac devices as well as promising urology products. Each one of these products addresses an opportunity of several hundred million dollars. Cardiac surgery The biodegradable Kalangos Rings for mitral and tricuspid valvuloplasty in adults and children is CE marked Cardiology Biodegradable stents for coronary arteries: in development Biodegradable membranes and support for percutaneous patent foramen ovale occlusion: in development Urology Biodegradable stents for male urethral implantation: in development Biodegradable prostheses for female urinary incontinence (FUI): in development